PMID- 27246604 OWN - NLM STAT- MEDLINE DCOM- 20170705 LR - 20181202 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 16 DP - 2016 Jun 1 TI - HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. PG - 241 LID - 10.1186/s12879-016-1567-2 [doi] LID - 241 AB - BACKGROUND: Human immunodeficiency virus (HIV) infection leads to more rapid progression of hepatitis C virus (HCV)-related liver fibrosis, which could be linked to differences in the severity of liver inflammation among HIV/HCV co-infected individuals compared to HCV mono-infected individuals. This study assessed the association of HIV co-infection with pro-inflammatory and pro-fibrogenic cytokines and chemokines during recent HCV infection. METHODS: Participants from the ATAHC study, a prospective cohort of recent HCV infection, with detectable HCV RNA at the time of acute HCV detection were included. Concentrations of 27 plasma cytokines and chemokines were measured by multiplex immunoassays and compared between those with, and without, HIV co-infection. RESULTS: Out of 117 individuals with recent HCV infection included in analysis, 73 had HCV mono-infection and 44 had HIV/HCV co-infection. Individuals with HIV/HCV co-infection had significantly higher mean levels of eotaxin (1.79 vs. 1.62 log pg/mL; P < 0.001), monocyte chemotactic protein 1 (MCP-1; 2.10 vs. 1.98 log pg/mL; P < 0.001), and interferon-gamma inducible protein-10 (IP-10; 3.11 vs. 2.98 log pg/mL; P = 0.013). Linear regression analyses adjusting for age, alanine transaminase (ALT), HCV RNA levels, and assay run, higher eotaxin levels were independently associated with HIV/HCV co-infection (adjusted beta: 0.12; 95%CI: 0.01, 0.24; P = 0.039). Higher MCP-1 levels were also independently associated with HIV/HCV co-infection in adjusted analysis (adjusted beta: 0.11; 95%CI: 0.03, 0.18; P = 0.009). CONCLUSIONS: During recent HCV, those with HIV/HCV co-infection had a stronger pro-fibrogenic mediator profile compared to those with HCV mono-infection. These findings may provide a potential explanation for accelerated liver fibrosis in HIV/HCV co-infection. TRIAL REGISTRATION: Australian Trial in Acute Hepatitis C (ATAHC) study was registered with ClinicalTrials.gov registry on September 11, 2005. NCT00192569 . FAU - Lamoury, Francois M J AU - Lamoury FM AD - The Kirby Institute, UNSW Australia, Sydney, Australia. flamoury@kirby.unsw.edu.au. AD - Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Australia, Sydney, NSW, 2010, Australia. flamoury@kirby.unsw.edu.au. FAU - Hajarizadeh, Behzad AU - Hajarizadeh B AD - The Kirby Institute, UNSW Australia, Sydney, Australia. FAU - Keoshkerian, Elizabeth AU - Keoshkerian E AD - Inflammation and Infection Research Centre, School of Medical Sciences, UNSW Australia, Sydney, Australia. FAU - Feld, Jordan J AU - Feld JJ AD - Toronto Centre for Liver Disease, McLaughlin-Rotman Centre for Global Health, University of Toronto, Toronto, Canada. FAU - Amin, Janaki AU - Amin J AD - The Kirby Institute, UNSW Australia, Sydney, Australia. FAU - Teutsch, Suzy AU - Teutsch S AD - Inflammation and Infection Research Centre, School of Medical Sciences, UNSW Australia, Sydney, Australia. FAU - Matthews, Gail V AU - Matthews GV AD - The Kirby Institute, UNSW Australia, Sydney, Australia. AD - HIV/Immunology/Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney, Australia. FAU - Hellard, Margaret AU - Hellard M AD - Burnet Institute, Melbourne, Australia. FAU - Dore, Gregory J AU - Dore GJ AD - The Kirby Institute, UNSW Australia, Sydney, Australia. AD - HIV/Immunology/Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney, Australia. FAU - Lloyd, Andrew R AU - Lloyd AR AD - Inflammation and Infection Research Centre, School of Medical Sciences, UNSW Australia, Sydney, Australia. FAU - Applegate, Tanya L AU - Applegate TL AD - The Kirby Institute, UNSW Australia, Sydney, Australia. FAU - Grebely, Jason AU - Grebely J AD - The Kirby Institute, UNSW Australia, Sydney, Australia. CN - ATAHC Study Group LA - eng SI - ClinicalTrials.gov/NCT00192569 GR - R01 DA015999/DA/NIDA NIH HHS/United States PT - Clinical Trial PT - Journal Article PT - Multicenter Study DEP - 20160601 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 RN - 0 (CCL11 protein, human) RN - 0 (CCL2 protein, human) RN - 0 (Chemokine CCL11) RN - 0 (Chemokine CCL2) RN - 82115-62-6 (Interferon-gamma) RN - EC 2.6.1.2 (Alanine Transaminase) SB - IM MH - Adult MH - Alanine Transaminase/blood MH - Australia MH - Chemokine CCL11/*blood MH - Chemokine CCL2/*blood MH - Coinfection/blood/virology MH - Female MH - HIV Infections/*blood/complications/virology MH - HIV-1 MH - Hepacivirus/immunology MH - Hepatitis C/*blood/complications/virology MH - Humans MH - Interferon-gamma/blood MH - Male MH - Middle Aged MH - Young Adult PMC - PMC4888248 OTO - NOTNLM OT - Acute infection OT - Chemokines OT - Co-infection OT - Cytokines OT - HCV EDAT- 2016/06/02 06:00 MHDA- 2017/07/06 06:00 PMCR- 2016/06/01 CRDT- 2016/06/02 06:00 PHST- 2015/11/09 00:00 [received] PHST- 2016/05/16 00:00 [accepted] PHST- 2016/06/02 06:00 [entrez] PHST- 2016/06/02 06:00 [pubmed] PHST- 2017/07/06 06:00 [medline] PHST- 2016/06/01 00:00 [pmc-release] AID - 10.1186/s12879-016-1567-2 [pii] AID - 1567 [pii] AID - 10.1186/s12879-016-1567-2 [doi] PST - epublish SO - BMC Infect Dis. 2016 Jun 1;16:241. doi: 10.1186/s12879-016-1567-2.